Objective  To study effect of levofloxacin combined with ambroxol on immunologic function and clinical efficacy in patients with chronic bronchitis(CB).

  Methods  A total of 138 patients with CB who were treated in our hospital were selected, and were randomly divided into observation group and control group, with 69 cases in each group. Patients of two groups were all treated with aminophylline, the control group was additionally given levofloxacin, and the observation group was given ambroxol based on the control group. The patients in two groups were treated for 1 week, and the clinical effects, level of immunologic function, C reactive protein (CRP) and interleukin-4 (IL-4) levels were compared, and the adverse reactions of the two groups were observed.

  Results  The total effective rate of the observation group was significantly higher than that of the control group 98.55% (68/69) vs. 89.86%(62/69), P < 0.05. After treatment, the levels of CD3⁺ and CD4⁺ of the two groups were significantly higher, while the CD8⁺ level was lower than treatment before, and observation group had better outcomes than the control group (P < 0.05). After treatment, CRP and IL-4 levels of two groups were significantly lower than before treatment, and the observation group was significantly lower than the control group (P < 0.05). The total incidence of adverse reactions in the observation group was 7.25%, and 13.04% in the control group, but no significant difference was observed(P>0.05).

  Conclusion  Levofloxacin combined with ambroxol in the treatment of patients with CB has better clinical efficacy, and can significantly improve the patient′s immunologic functionand the level of inflammatory indicators, and is safer.